Elekta

STOCKHOLM – Elekta (EKTA-B.ST) announces that it has successfully closed its inaugural sustainability-linked revolving credit facility (the “facility”) for EUR 250 million. The facility is based on both social and environmental key performance indicators (KPIs) and follows on Elekta’s sustainability-linked bond, issued in 2021, which was oversubscribed.
 
The facility is linked to KPIs such as:

• increasing access to radiotherapy in underserved markets through the installation of linear accelerators,
• reducing absolute Scope 1 & 2* emissions,
• increasing the proportion of Elekta’s suppliers that have science-based emission reduction targets.

Hilma Nordquist, Elekta’s Group Sustainability Director, says: “Sustainability is an integral part of our ACCESS 2025 strategy, and we are pleased to closely link it to our financing. The deal underlines the confidence in Elekta’s financial and sustainability performance and our commitment to sustainable business practices and willingness to drive positive impact.”
 
This sustainability-linked refinancing reflects Elekta’s commitment to reduce greenhouse gas emissions, which was recently validated by the Science Based Targets initiative (SBTi).
 
The facility has an initial tenor of five years and includes two one-year extension options. The Bank of America Europe DAC acted as sole Coordinator, Sustainability Coordinator and Documentation Agent, while Danske Bank A/S will act as the Facility Agent.
 
*Scope 1 (direct emissions) and Scope 2 (indirect emissions from purchased energy) cover emissions across the company’s operations.
 
# # #
 
For further information, please contact:
Mattias Thorsson, Vice President, Head of Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com 
Time zone: CET: Central European Time
 
Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.com
Time zone: CET: Central European Time
 
About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on Twitter.